RU2394031C2 - Соли четвертичного аммония в качестве антагонистов м3 - Google Patents
Соли четвертичного аммония в качестве антагонистов м3 Download PDFInfo
- Publication number
- RU2394031C2 RU2394031C2 RU2007128085/04A RU2007128085A RU2394031C2 RU 2394031 C2 RU2394031 C2 RU 2394031C2 RU 2007128085/04 A RU2007128085/04 A RU 2007128085/04A RU 2007128085 A RU2007128085 A RU 2007128085A RU 2394031 C2 RU2394031 C2 RU 2394031C2
- Authority
- RU
- Russia
- Prior art keywords
- hydroxy
- phenyl
- formula
- cyclohexyl
- methyl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims abstract 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims abstract 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000002947 alkylene group Chemical group 0.000 claims abstract 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000005842 heteroatom Chemical group 0.000 claims abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 5
- 239000001301 oxygen Chemical group 0.000 claims abstract 5
- 239000011593 sulfur Chemical group 0.000 claims abstract 5
- 229910052717 sulfur Chemical group 0.000 claims abstract 5
- 239000000126 substance Substances 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 claims abstract 2
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 claims abstract 2
- 230000003042 antagnostic effect Effects 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- -1 2-cyclohexyl-2-hydroxy-2-phenylacetoxymethyl Chemical group 0.000 claims 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- BMFFANCEZMKBHT-UHFFFAOYSA-N [1-methyl-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate bromide Chemical compound [Br-].OC(C(=O)OCC1[N+](CCC1)(C)CC(NC1=NOC=C1)=O)(C1=CC=CC=C1)C1=CC=CC=C1 BMFFANCEZMKBHT-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 abstract 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 abstract 2
- 229930192474 thiophene Natural products 0.000 abstract 2
- 150000003577 thiophenes Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0428418.8A GB0428418D0 (en) | 2004-12-24 | 2004-12-24 | Organic compounds |
| GB0428418.8 | 2004-12-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007128085A RU2007128085A (ru) | 2009-01-27 |
| RU2394031C2 true RU2394031C2 (ru) | 2010-07-10 |
Family
ID=34130968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007128085/04A RU2394031C2 (ru) | 2004-12-24 | 2005-12-22 | Соли четвертичного аммония в качестве антагонистов м3 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8153669B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1831208B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008525359A (cg-RX-API-DMAC7.html) |
| KR (1) | KR101259654B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101080405B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE521606T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005318424B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0519292A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2589133A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2370832T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0428418D0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007007722A (cg-RX-API-DMAC7.html) |
| PL (1) | PL1831208T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1831208E (cg-RX-API-DMAC7.html) |
| RU (1) | RU2394031C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006066929A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US12195428B2 (en) | 2019-03-11 | 2025-01-14 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0428416D0 (en) | 2004-12-24 | 2005-02-02 | Novartis Ag | Organic compounds |
| KR101495708B1 (ko) | 2007-02-23 | 2015-02-25 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 무스카린 수용체 안타고니스트로 유용한 4차 암모늄 디페닐메틸 화합물 |
| MX2010002576A (es) | 2007-09-07 | 2010-04-01 | Theravance Inc | Compuestos que contienen guanidina, utiles como antagonistas de los receptores muscarinicos. |
| EP2222637A1 (en) | 2007-12-14 | 2010-09-01 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
| DE102008020746A1 (de) | 2008-04-25 | 2009-10-29 | Saltigo Gmbh | Verfahren zur Herstellung von quarternären Salzen von Piperidyl Estern der Mandelsäure |
| EP2935249B1 (en) | 2012-12-19 | 2018-12-12 | Novartis AG | Autotaxin inhibitors |
| JP6223543B2 (ja) | 2013-03-15 | 2017-11-01 | ボドール ラボラトリーズ, インコーポレイテッド | 多汗症の処置のための抗コリン作用性グリコピロレートエステル |
| US20160368873A1 (en) * | 2014-02-17 | 2016-12-22 | Ltt Bio-Pharma Co., Ltd. | Optically Active Form of Mepenzolate, and Ameliorating Agent for Chronic Obstructive Pulmonary Disease Which Contains Same as Active Ingredient |
| US20150259283A1 (en) | 2014-03-13 | 2015-09-17 | Brickell Biotech, Inc. | Formulation for soft anticholinergic analogs |
| EP3134398A1 (en) | 2014-04-24 | 2017-03-01 | Novartis Ag | Autotaxin inhibitors |
| US10472664B2 (en) | 2014-10-03 | 2019-11-12 | Institute For Cancer Research | Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors |
| EP3200792A4 (en) | 2014-10-03 | 2018-05-09 | The Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center | Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad |
| HK1253236A1 (zh) | 2015-07-21 | 2019-06-14 | 博多尔实验仪器公司 | 软性抗胆碱能药类似物的制剂 |
| TWI719046B (zh) | 2016-07-21 | 2021-02-21 | 美商波德實驗股份有限公司 | 軟性抗膽鹼類似物之製劑 |
| CA3155568A1 (en) | 2019-11-06 | 2021-05-14 | Bridget Mccarthy Cole | Charged ion channel blockers and methods for use |
| US11332446B2 (en) * | 2020-03-11 | 2022-05-17 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2746966A (en) * | 1953-11-02 | 1956-05-22 | Lakeside Lab Inc | Esters of bis-(nu-substituted-3-hydroxypiperidinium) alkanes |
| EP0073645A2 (en) * | 1981-08-26 | 1983-03-09 | Dainippon Pharmaceutical Co., Ltd. | 2-Cyclic amino-2-(1,2-benzisoxazol-3-yl)acetic acid ester derivatives, process for the preparation thereof and composition containing the same |
| EP1302458A1 (en) * | 2000-07-11 | 2003-04-16 | Banyu Pharmaceutical Co., Ltd. | Ester derivatives |
| WO2003087094A2 (en) * | 2002-04-16 | 2003-10-23 | Almirall Prodesfarma Ag | Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors |
| RU2238936C2 (ru) * | 1996-11-11 | 2004-10-27 | Кристиан Р. НОЕ | Энантиомерно чистые основные эфиры арил-циклоалкилгидроксикарбоновых кислот, способ их получения и применение в лекарственных средствах |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB833820A (en) * | 1957-10-17 | 1960-04-27 | Beecham Res Lab | Improvements in or relating to the preparation of pyrrolidyl esters and quaternary compounds thereof |
| US2956062A (en) * | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| JPS6018661B2 (ja) | 1976-01-01 | 1985-05-11 | 太田製薬株式会社 | 1−(1,3−ジオキソラン−4−イルメチル)ピペリジノ−ル誘導体 |
| JPS5427570A (en) | 1977-07-30 | 1979-03-01 | Ota Pharma | Stereoisomer of 44acyloxyy11 alkyll11*1*33dioxolanee44 ylmethyl* pideridinium salt derivative |
| JPS5679688A (en) | 1979-12-04 | 1981-06-30 | Ota Seiyaku Kk | 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production |
| JPS58208270A (ja) | 1982-05-28 | 1983-12-03 | Dainippon Pharmaceut Co Ltd | α−環状アミノフエニル酢酸エステル類並びにその酸付加塩類及び第4級アンモニウム塩類 |
| GB9023023D0 (en) | 1990-10-23 | 1990-12-05 | Barlow Richard B | Pharmaceutical compositions |
| WO2004056767A1 (en) * | 2002-12-23 | 2004-07-08 | Ranbaxy Laboratories Limited | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists |
| PE20050231A1 (es) * | 2003-06-24 | 2005-05-20 | Novartis Ag | Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 |
| EP1781607A2 (en) * | 2004-08-19 | 2007-05-09 | Ranbaxy Laboratories Limited | Pyrrolidine derivatives as muscarinic receptor antagonists |
-
2004
- 2004-12-24 GB GBGB0428418.8A patent/GB0428418D0/en not_active Ceased
-
2005
- 2005-12-22 KR KR1020077014261A patent/KR101259654B1/ko not_active Expired - Fee Related
- 2005-12-22 PT PT05820639T patent/PT1831208E/pt unknown
- 2005-12-22 RU RU2007128085/04A patent/RU2394031C2/ru not_active IP Right Cessation
- 2005-12-22 WO PCT/EP2005/013897 patent/WO2006066929A1/en not_active Ceased
- 2005-12-22 CA CA002589133A patent/CA2589133A1/en not_active Abandoned
- 2005-12-22 JP JP2007547368A patent/JP2008525359A/ja active Pending
- 2005-12-22 ES ES05820639T patent/ES2370832T3/es not_active Expired - Lifetime
- 2005-12-22 US US11/721,989 patent/US8153669B2/en not_active Expired - Fee Related
- 2005-12-22 AU AU2005318424A patent/AU2005318424B2/en not_active Ceased
- 2005-12-22 MX MX2007007722A patent/MX2007007722A/es active IP Right Grant
- 2005-12-22 AT AT05820639T patent/ATE521606T1/de active
- 2005-12-22 EP EP05820639A patent/EP1831208B1/en not_active Expired - Lifetime
- 2005-12-22 BR BRPI0519292-7A patent/BRPI0519292A2/pt not_active IP Right Cessation
- 2005-12-22 PL PL05820639T patent/PL1831208T3/pl unknown
- 2005-12-22 CN CN2005800429764A patent/CN101080405B/zh not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2746966A (en) * | 1953-11-02 | 1956-05-22 | Lakeside Lab Inc | Esters of bis-(nu-substituted-3-hydroxypiperidinium) alkanes |
| EP0073645A2 (en) * | 1981-08-26 | 1983-03-09 | Dainippon Pharmaceutical Co., Ltd. | 2-Cyclic amino-2-(1,2-benzisoxazol-3-yl)acetic acid ester derivatives, process for the preparation thereof and composition containing the same |
| RU2238936C2 (ru) * | 1996-11-11 | 2004-10-27 | Кристиан Р. НОЕ | Энантиомерно чистые основные эфиры арил-циклоалкилгидроксикарбоновых кислот, способ их получения и применение в лекарственных средствах |
| EP1302458A1 (en) * | 2000-07-11 | 2003-04-16 | Banyu Pharmaceutical Co., Ltd. | Ester derivatives |
| WO2003087094A2 (en) * | 2002-04-16 | 2003-10-23 | Almirall Prodesfarma Ag | Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors |
Non-Patent Citations (1)
| Title |
|---|
| WAELBROECK M et al. BRITISH JOURNAL OF PHARMACOLOGY, vol.105, №1, 1992, p. 97-102. SUGAI S et al. CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, vol.32, № 3, 1984, p. 977-985. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12195428B2 (en) | 2019-03-11 | 2025-01-14 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
Also Published As
| Publication number | Publication date |
|---|---|
| US8153669B2 (en) | 2012-04-10 |
| PL1831208T3 (pl) | 2012-01-31 |
| BRPI0519292A2 (pt) | 2009-01-06 |
| EP1831208B1 (en) | 2011-08-24 |
| RU2007128085A (ru) | 2009-01-27 |
| JP2008525359A (ja) | 2008-07-17 |
| EP1831208A1 (en) | 2007-09-12 |
| AU2005318424A1 (en) | 2006-06-29 |
| AU2005318424B2 (en) | 2009-10-08 |
| KR20070089953A (ko) | 2007-09-04 |
| ES2370832T3 (es) | 2011-12-23 |
| CN101080405B (zh) | 2011-05-11 |
| PT1831208E (pt) | 2011-10-31 |
| GB0428418D0 (en) | 2005-02-02 |
| HK1109767A1 (en) | 2008-06-20 |
| ATE521606T1 (de) | 2011-09-15 |
| CN101080405A (zh) | 2007-11-28 |
| MX2007007722A (es) | 2007-08-14 |
| US20090227590A1 (en) | 2009-09-10 |
| CA2589133A1 (en) | 2006-06-29 |
| KR101259654B1 (ko) | 2013-04-30 |
| WO2006066929A1 (en) | 2006-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2214400C2 (ru) | Производные 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способы их получения, фармацевтическая композиция на их основе и промежуточные вещества | |
| RU2403247C2 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| RU2399620C2 (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| EA200501332A1 (ru) | Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38 | |
| RU2003132687A (ru) | Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv | |
| RU2013119129A (ru) | Органические соединения | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| PE20060693A1 (es) | Nuevos derivados de trifluorometansulfonanilida oxamida eter | |
| EE200300403A (et) | N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina | |
| AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| EA200500088A1 (ru) | Трициклические модуляторы ядерного рецептора стероидного гормона | |
| RU2011150654A (ru) | Композиции для лечения злоупотребления веществами, вызывающими болезненное пристрастие, и улучшения поведения, связанного со злоупотреблениями | |
| RU2010126105A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства | |
| RU2007106180A (ru) | Производные индола, индазола или индолина | |
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| RU2011102396A (ru) | Аминосоединения и их медицинское применение | |
| SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| RU2007128085A (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| RU2006130000A (ru) | Органические соединения | |
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| SE0301701D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| RU2005122615A (ru) | Соединения n-(индолэтил)циклоамина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20141223 |